Inhibition of guanosine monophosphate synthetase (GMPS) blocks glutamine metabolism and prostate cancer growth
Glutamine is a critical nutrient in cancer, however its contribution to purine metabolism in prostate cancer has not previously been determined. Guanosine monophosphate synthetase (GMPS) acts in the de novo purine biosynthesis pathway, utilizing a glutamine amide to synthesize the guanine nucleotide. This study demonstrates that GMPS mRNA expression correlates with Gleason score in prostate cancer samples, while high GMPS expression was associated with decreased rates of overall and disease/progression-free survival. Pharmacological inhibition or knockdown of GMPS significantly decreased cell growth in both LNCaP and PC-3 prostate cancer cells. We utilized (15) N-(amide)-glutamine and U-(13) C5 -glutamine metabolomics to dissect the pathways involved, and despite similar growth inhibition by GMPS knockdown, we show unique metabolic effects across each cell line. Using a PC-3 xenograft mouse model, tumor growth was also significantly decreased after GMPS knockdown, highlighting the importance of glutamine metabolism and providing support for GMPS as a therapeutic target in prostate cancer. This article is protected by copyright. All rights reserved.
|ISBN||1096-9896 (Electronic) 0022-3417 (Linking)|
|Authors||Wang, Q.; Guan, Y. F.; Hancock, S. E.; Wahi, K.; van Geldermalsen, M.; Zhang, B. K.; Pang, A.; Nagarajah, R.; Mak, B.; Freidman, N.; Horvath, L. G.; Turner, N.; Holst, J.|
|Responsible Garvan Author|
|Publisher Name||JOURNAL OF PATHOLOGY|
|URL link to publisher's version||https://www.ncbi.nlm.nih.gov/pubmed/33768538|